CLPTM1L and ovarian neoplasm: Using flow cytometry, gated as shown in Supplementary Fig. 3, binding of full-length human anti-CLPTM1L (102-5) to the surface of live human ovarian tumor cells (A2780) was demonstrated (Fig. 2c).